COLLEGIUM PHARMACEUTICAL, INC — Director's Dealing 2015

May 12, 2015

SEC Form 3/A — Form 3/A

Issuer: COLLEGIUM PHARMACEUTICAL, INC (COLL)
CIK: 0001267565
Period of Report: 2015-05-06

Reporting Person: Skyline Venture Partners V LP (10% Owner)
Reporting Person: Skyline Venture Management V, LLC (10% Owner)
Reporting Person: KANEKO YASUNORI (10% Owner)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series B Convertible Preferred Stock	$		Common Stock (1552795)		Indirect
Series C Convertible Preferred Stock	$		Common Stock (382323)		Indirect
Series D Convertible Preferred Stock	$		Common Stock (852423)		Indirect

Footnotes

F1: All series of Convertible Preferred Stock will automatically convert into Collegium Pharmaceutical, Inc. common stock on a 1-for-6.9 basis immediately prior to the closing of the initial public offering and have no expiration date.

F2: The shares are held by Skyline Venture Partners V, L.P. The general partner of Skyline Venture Partners V, L.P. is Skyline Venture Management V, LLC. John G. Freund and Yasunori Kaneko are managers of Skyline Venture Management V, LLC. These individuals share voting and investment power over the shares held by Skyline Venture Management, LLC and disclaim beneficial ownership of all the shares held by Skyline Venture Partners V, L.P. except to the extent of their proportionate pecuniary interest therein. Dr. Freund is a director of the Issuer and, accordingly, files separate Section 16 reports.